Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135434 · ClinicalTrials.gov registry record · Phase 1
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
A Phase 1 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00135434: Completed Phase 1 study of HIV Infections, sponsored by Bristol-Myers Squibb.
NCT00135434 is a Phase 1 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 25 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00135434, a Phase 1 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
Conditions Studied
Interventions
- DRUG Atazanavir/Ritonavir/Lopinavir/ritonavir
Study Locations (1)
New Jersey
- Clinical Pharmacology Unit, Bristol-Myers Squibb Company - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
What the finished NCT00135434 record still lists
NCT00135434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Atazanavir/Ritonavir/Lopinavir/ritonavir is the first listed.
NCT00135434 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00135434 about?
NCT00135434 is a clinical study titled "Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism". This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
What is the current status of trial NCT00135434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-09. Estimated completion is 2005-06.
What conditions does trial NCT00135434 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00135434?
The interventions under investigation include: Atazanavir/Ritonavir/Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00135434?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00135434 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00135434's enrollment target sits among peer trials
25 461st of 542 higher than 74 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia